PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

This study has been withdrawn prior to enrollment.
(PI left institution)
Sponsor:
Collaborators:
Cephalon
GlaxoSmithKline
Information provided by:
Nevada Cancer Institute
ClinicalTrials.gov Identifier:
NCT01131247
First received: May 25, 2010
Last updated: July 19, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given